These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37566903)

  • 1. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
    Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
    J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
    Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
    Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects.
    Anliker-Ort M; Dingemanse J; Janů L; Kaufmann P
    Clin Drug Investig; 2023 Nov; 43(11):827-837. PubMed ID: 37858005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
    Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
    Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers.
    Gao L; Kaushik D; Ingalls K; Milner S; Smith N; Kong R
    Drugs R D; 2024 Sep; 24(3):477-487. PubMed ID: 39316278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
    Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib.
    Long A; Yamamiya I; Valentine M; Machnes Z; Hangai N; Anderson B; Wacheck V; Gao L
    Clin Transl Sci; 2024 Sep; 17(9):e70012. PubMed ID: 39258521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
    Choi H; Huang F; Flack M
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
    Harvey RD; Aransay NR; Isambert N; Lee JS; Arkenau T; Vansteenkiste J; Dickinson PA; Bui K; Weilert D; So K; Thomas K; Vishwanathan K
    Br J Clin Pharmacol; 2018 Dec; 84(12):2877-2888. PubMed ID: 30171779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
    Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
    Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.
    Sechaud R; Gu H; Rahmanzadeh G; Chiparus O; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):535-547. PubMed ID: 39110203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate.
    Lee L; Murase K; Ma J; Thoolen M
    Clin Pharmacol Drug Dev; 2023 Mar; 12(3):279-286. PubMed ID: 36478438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
    Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
    J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
    Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
    Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.